Welcome to our dedicated page for 23Andme Holding Co news (Ticker: ME), a resource for investors and traders seeking the latest updates and insights on 23Andme Holding Co stock.
23andMe Holding Co (NASDAQ: ME) provides cutting-edge personal genomics services through direct-to-consumer DNA testing kits and collaborative health research. This news hub aggregates official announcements, financial disclosures, and strategic developments for stakeholders tracking the company's progress in biotechnology and digital health.
Access timely updates including quarterly earnings reports, new product launches, and research partnerships with pharmaceutical leaders. The curated collection serves as a reliable resource for understanding 23andMe's operational milestones, scientific contributions, and market positioning.
Key content categories include regulatory filings, genetic database expansion announcements, and innovations in preventive health insights. Investors will find essential updates on the company's dual focus areas: consumer-facing genetic reports and data-driven therapeutic research initiatives.
Bookmark this page for streamlined access to 23andMe's latest developments, featuring verified information about their industry-leading genetic testing services and contributions to precision medicine research. Regular updates ensure you stay informed about this pioneer in consumer-driven healthcare innovation.
23andMe (Nasdaq: ME) announced positive nonclinical data for its first-in-class antibody 23ME-01473 at the ESMO Congress 2024. The antibody, targeting the NKG2D ligand ULBP6, showed inhibition of tumor growth in a non-small cell lung cancer mouse model. Elevated levels of ULBP6 were confirmed in squamous cell carcinomas and some adenocarcinomas, guiding potential clinical indications. The ongoing Phase 1/2a trial, which began in March 2024, has prioritized four expansion cohort cancer types: head and neck squamous cell carcinoma, squamous non-small cell lung cancer, colorectal cancer, and triple-negative breast cancer. This data supports the potential of human genetics in identifying new targets for immuno-oncology drug development.
23andMe (Nasdaq: ME) announced positive preliminary Phase 2 safety and efficacy data for 23ME-00610, a first-in-class anti-CD200R1 antibody, at the ESMO Congress 2024. Key findings include:
1. A confirmed partial response in a patient with refractory clear-cell renal-cell carcinoma (ccRCC).
2. Acceptable safety and tolerability profile.
3. Higher tumor expression of CD200 may be associated with clinical benefit.
4. Potential effectiveness in 'cold' tumors, suggesting opportunity for patients unable to benefit from PD-1/PD-L1 checkpoint inhibitors.
The study included 10 ccRCC patients and 13 patients with TMB-H or MSI-H cancers. The data suggests that interrupting the CD200/CD200R1 pathway has potential to reverse immune suppression in the tumor microenvironment.
23andMe, in collaboration with the National Human Genome Research Institute and Johns Hopkins University, conducted one of the largest and most diverse studies on sickle cell trait (SCT) and its association with venous thromboembolism (VTE). The study, published in Blood Advances, analyzed data from 4.2 million research-consented participants, including 19,000 with SCT.
Key findings include:
- SCT is a modest risk factor for blood clots across diverse populations
- Individuals with SCT have a lower risk of VTE compared to carriers of factor V Leiden
- SCT is associated with pulmonary emboli (PE) but not deep vein thrombosis (DVT)
- The study suggests a unique mechanism of blood clotting in people with SCT
This research provides valuable information for clinicians counseling individuals with SCT and highlights the importance of inclusive genetic research.
23andMe (Nasdaq: ME) will present updates on its clinical immuno-oncology programs at the ESMO Congress 2024 in Barcelona. The company will showcase three posters on 23ME-00610, a first-in-class anti-CD200R1 antibody, and two on 23ME-01473, an anti-ULBP6 monoclonal antibody.
Key highlights include:
- Preliminary efficacy data for 23ME-00610 in renal cancer and TMB-H/MSI-H cohorts
- Analysis of CD200 as a potential biomarker for 23ME-00610 efficacy
- Preclinical data on 23ME-01473 and its ongoing Phase 1/2a dose escalation study
Both drug candidates were discovered using 23andMe's proprietary database of human genetic and health information, leveraging data from over 15 million genotyped customers.
Lemonaid Health, a subsidiary of 23andMe (Nasdaq: ME), is now offering GLP-1 medications including Ozempic®, Wegovy®, and compounded semaglutide through a weight loss program on its telehealth platform. The program provides a $49 monthly membership with access to clinician consultations, prescriptions, and ongoing support. Medication costs start at $299 per month for compounded semaglutide.
Concurrently, 23andMe launched a study to investigate the genetic factors influencing GLP-1 effectiveness and side effects. The company aims to uncover insights for personalized weight loss treatments and preventive health strategies. GLP-1 medications have shown potential benefits beyond weight loss, including treatment of type 2 diabetes, heart disease, and possibly Parkinson's, arthritis, Alzheimer's, and sleep apnea.
23andMe (NASDAQ:ME) faced a major data breach in December 2023, affecting approximately 7 million users. A class action lawsuit reveals that hackers specifically targeted Jewish and Chinese customers, compiling and selling their personal genetic information on the dark web. The breach included a leak of over 1 million Jewish customers and 350,000 Chinese customers. The company allegedly concealed these details when notifying affected users. The lawsuit claims 23andMe has not informed compromised customers about the specific targeting or the dark web disclosure. The hacked data included genetic heritage, names, addresses, phenotype and health information, photos, and identification data.
23andMe (NASDAQ: ME) faced a significant data breach in December 2023, affecting approximately 7 million users of its genetic services website. A recently filed class complaint reveals that hackers specifically targeted the personal genetic information of Jewish and Chinese customers. The breach resulted in the compilation and sale of sensitive data on the dark web, including a list of over 1 million Jewish customers and 350,000 Chinese customers. The lawsuit alleges that 23andMe concealed these details when notifying affected customers and has not informed them about the specific targeting or the extent of the data exposure on the dark web.
23andMe (NASDAQ:ME) faced a significant data breach in December 2023, affecting approximately 7 million users of its genetic services website. A recently filed class complaint alleges that hackers specifically targeted the personal genetic information of Jewish and Chinese customers, compiling and selling this data on the dark web. The breach reportedly included a list of over 1 million Jewish customers and 350,000 Chinese customers. The lawsuit claims 23andMe has not fully informed affected customers about the extent of the breach or the targeted nature of the attack. The disclosure poses potential safety risks, particularly for Chinese citizens. Legal action is being pursued for affected individuals, especially those with Ashkenazi Jewish heritage or Chinese ancestry in specific states.
23andMe Holding Co. (Nasdaq: ME) reported Q1 FY2025 financial results, showing a 34% decrease in total revenue to $40 million. This decline was primarily due to lower research revenue after the GSK collaboration conclusion and reduced consumer revenue. Key developments include:
1. Launch of a genetic research study on GLP-1 medications
2. Introduction of a GLP-1 weight loss telehealth membership
3. Addition of a Biological Age feature to Total Health offering
4. New genetic Polygenic Risk Score report for bipolar disorder
5. Collaboration with Nightingale Health for metabolomics blood biomarker panel
6. Progress in therapeutics programs with data presentations at AACR and ASCO
Operating expenses decreased to $92 million, and net loss improved to $69 million. The company ended the quarter with $170 million in cash and cash equivalents.
23andMe (NASDAQ: ME) faced a major data breach in December 2023, affecting approximately 7 million users. A class action lawsuit alleges that hackers specifically targeted Jewish and Chinese customers' genetic information, compiling and selling it on the dark web. The breach reportedly exposed data of over 1 million Jewish customers and 350,000 Chinese customers.
Key points:
- Hackers targeted personal genetic information, names, and addresses of Jewish and Chinese customers
- Data was sold on the dark web, with prices ranging from $1,000 for 100 profiles to $100,000 for 100,000 profiles
- 23andMe allegedly concealed the targeted nature of the breach when notifying affected customers
- The company initially blamed the breach on customers using recycled login credentials
- A class action lawsuit is being pursued for affected customers, particularly those with Ashkenazi Jewish heritage or Chinese ancestry
